ClinicalTrials.gg
RecruitingNCT05708001Updated Jul 15, 2025

Improvement of Memory in Mild Cognitive Impairment

An interventional study of transcranial alternating current stimulation (tACS) and high-density electroencephalography (hdEEG) in Mild Cognitive Impairment, sponsored by Lucie Bréchet. Recruiting at 1 site in Switzerland. Open to participants aged 55 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by Lucie Bréchet · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Cognitive Dysfunction with a site in Switzerland — 17 open to participants now, 21 under way, 3 of them phase 3. Cognitive Dysfunction · Switzerland.

Planned enrollment
33rd of 48
40 · median 56
Started
2023
with 8 others
No phase
38 of 61
13 open now
Primary completion
2027-09
later than 11 of 20 live
Registered
39th of 61
by date
Lead sponsor
2 of 61
Lucie Bréchet

Among the 61 studies in Cognitive Dysfunction with a site in Switzerland, this one is the 33rd largest by planned enrollment of the 48 interventional ones that give a count, is one of 9 that started in 2023, is one of 38 with no phase, reaches primary completion later than 11 of the 20 other live ones, and was the 39th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

17 of the 61 studies in Cognitive Dysfunction with a site in Switzerland are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Cognitive Dysfunction with a site in Switzerland, or all of them as a file.
02

Study summary

The Clinical Trial will systematically examine the feasibility of remote, caregiver-led tACS for older adults with memory deficits and evaluate whether repeated tACS leads to sustained improvement of neuronal activity and memory functions.

Read the detailed description

The proposed investigation will systematically examine the feasibility and efficacy of remote, caregiver-led tACS for older adults with memory decline. This study will provide data to support the safety and effectiveness of home-based tACS in this population and will lead to future research to increase access to tACS as a part of memory decline prevention and treatment for older adults.

03

Conditions studied

  • Mild Cognitive Impairment

Keywords

  • autobiographical memory (ABM)
  • memory and cognition
  • transcranial alternating current stimulation (tACS)
  • high-density electroencephalography (hdEEG)
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Mild Cognitive Impairment (MCI) patients

  • age ≥ 55 years old
  • clinical diagnosis of mild cognitive impairment (MCI) based on a comprehensive clinical assessment and standard neuropsychological examination including tests of language, visuospatial thinking, executive functions, and memory
  • confirmation of diagnosis will be made by Prof. Paul Unschuld, the study MD, based on a participant's cognitive evaluation and history
  • understanding of the
  • able and willing to comply with all study requirements
  • informed consent form was signed
  • women of (WOCBP) must perform a pregnancy test during screening

Caregiver

  • minimum 21 years of age
  • self-reported computer/tablet proficiency
  • willingness to learn how to use tACS
  • availability during the study period to administer tACS to the participant
  • informed consent form was signed
  • women of childbearing potential (WOCBP) must perform a pregnancy test during screening

Exclusion criteria

Exclusion Criteria:

Mild Cognitive Impairment (MCI) patients

  • age \< 55 years old
  • any current diagnosis of a psychiatric disorder (e.g., schizophrenia, bipolar disorder, depressive disorder)
  • other than MCI, any history of other progressive or genetic neurologic disorder (e.g., Parkinson's disease, multiple sclerosis, tubular sclerosis) or acquired neurological disease (e.g., stroke, traumatic brain injury, tumor), including intracranial lesions
  • history of head trauma resulting in prolonged loss of consciousness
  • current history of poorly controlled headaches including chronic medication for migraine prevention
  • history of fainting spells of unknown or undetermined etiology that might constitute seizures
  • history of seizures, diagnosis of epilepsy
  • any unstable medical condition or chronic uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
  • for undergoing MRI or receiving tACS
  • any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g., MRI compatible joint replacement)
  • any skin problems, such as dermatitis, psoriasis, or eczema
  • any electrically, magnetically, or mechanically activated implanted devices such as a pacemaker, intracranial electrodes, implanted defibrillators, medication pumps, nerve stimulators, vascular clips, or any other prosthesis in the brain
  • any serious life-threatening disease such as congestive heart failure, pulmonary obstructive chronic disease, or active neoplasia
  • pregnant women
  • adults lacking capacity for consent

Caregiver

  • insufficient understanding of study procedures
  • poor eyesight, severe arthritis in the hands, pain, deformity or other condition that interferes with successful administration of tACS
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Transcranial alternating current stimulation (tACS)

    The randomized, sham-controlled, parallel-arm, double-blind clinical trial will include 4 weeks of daily, home-based stimulation sessions. MCI patients will be randomly assigned to the active or sham group.

    Device: transcranial alternating current stimulation (tACS)

  • Experimental
    neurophysiological (hdEEG)

    At the baseline and after 4 weeks, MCI patients will be evaluated in the laboratory using hdEEG.

    Device: high-density electroencephalography (hdEEG)

  • Experimental
    clinical measures (MoCA)

    At the baseline and after 4 weeks, MCI patients will be evaluated in the laboratory using MoCA.

    Diagnostic Test: Montreal Cognitive Assessment (MoCA)

Interventions

  • Devicetranscranial alternating current stimulation (tACS)

    tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance. Two tACS (active and sham) conditions will be applied in randomized order. 40 Hz tACS will be delivered to different brain areas of the memory network. We will employ a multielectrode montage based on electric field modeling using the individual MRI to optimally reach the target areas. The maximum injected current per electrode is 2mA and the overall maximal current is 4mA to generate an average electric field of 0.25 V/m.

  • Devicehigh-density electroencephalography (hdEEG)

    EEG will be recorded with a 257-channel EEG system. An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek. The net contains Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touch the participant's scalp surface directly. Net application takes about 10 min to derive to impedances of \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between DC-200 Hz. Vertex electrode Cz is used as an acquisition reference.

  • Diagnostic testMontreal Cognitive Assessment (MoCA)

    Clinical Evaluation and Cognitive Assessment - to characterize the level of dementia and changes in cognitive status measured at the baseline and after 4 weeks of gamma/sham tACS intervention, and in a follow-up 3 months after the stimulation using MoCA.

06

What researchers measure

Primary outcomes

  1. cognitive status measured by Montreal Cognitive Assessment (MoCA)

    The primary objective is to characterize cognitive status at baseline and after 4 weeks of the home-based stimulation intervention.

    Time frame: baseline, after 4 weeks

Secondary outcomes

  1. modulation of gamma activity assessed with high-density EEG

    The secondary objective is to assess with hdEEG any changes in gamma power at baseline and after 4 weeks of the home-based stimulation intervention.

    Time frame: baseline, after 4 weeks,

07

Study locations

1 of 1 sites recruiting
  • University of Geneva, Campus Biotech
    Geneva, 1202, Switzerland
    Recruiting
    • Lucie Bréchet, PhD · Contact
    • Lucie Bréchet, PhD · Principal investigator
    • Paul G Unschuld, PhD · Sub investigator
08

References and documents

Publications

  • Brechet L, Brunet D, Birot G, Gruetter R, Michel CM, Jorge J. Capturing the spatiotemporal dynamics of self-generated, task-initiated thoughts with EEG and fMRI. Neuroimage. 2019 Jul 1;194:82-92. doi: 10.1016/j.neuroimage.2019.03.029. Epub 2019 Mar 19. PubMed 30902640 ↗
  • Brechet L, Michel CM, Schacter DL, Pascual-Leone A. Improving autobiographical memory in Alzheimer's disease by transcranial alternating current stimulation. Curr Opin Behav Sci. 2021 Aug;40:64-71. doi: 10.1016/j.cobeha.2021.01.003. Epub 2021 Feb 14. PubMed 34485630 ↗
  • Brechet L, Yu W, Biagi MC, Ruffini G, Gagnon M, Manor B, Pascual-Leone A. Patient-Tailored, Home-Based Non-invasive Brain Stimulation for Memory Deficits in Dementia Due to Alzheimer's Disease. Front Neurol. 2021 May 20;12:598135. doi: 10.3389/fneur.2021.598135. eCollection 2021. PubMed 34093384 ↗
  • Benussi A, Cantoni V, Grassi M, Brechet L, Michel CM, Datta A, Thomas C, Gazzina S, Cotelli MS, Bianchi M, Premi E, Gadola Y, Cotelli M, Pengo M, Perrone F, Scolaro M, Archetti S, Solje E, Padovani A, Pascual-Leone A, Borroni B. Increasing Brain Gamma Activity Improves Episodic Memory and Restores Cholinergic Dysfunction in Alzheimer's Disease. Ann Neurol. 2022 Aug;92(2):322-334. doi: 10.1002/ana.26411. Epub 2022 Jun 6. PubMed 35607946 ↗
  • Bouhour C, Konstantopoulou S, Piton T, Tingaud M, Mauriello C, Lory K, Unschuld PG, Brechet L. Family caregiver perspectives on administering home-based stimulation in patients with mild cognitive impairment. J Alzheimers Dis. 2026 May;111(1):249-257. doi: 10.1177/13872877261429857. Epub 2026 Mar 15. PubMed 41834385 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Sep 2027, 55 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 55 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2023
First posted
Feb 1, 2023
StartActual
Feb 1, 2023
Primary completionEst.
Sep 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05708001
Lead sponsor
Lucie Bréchet
Responsible party
Lucie Bréchet (Sponsor-Investigator, University of Geneva, Switzerland) — Sponsor-investigator
First posted
Feb 1, 2023
Start date
Feb 1, 2023
Primary completion
Sep 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jul 15, 2025

Study contacts

Lucie Bréchet, PhD
Contact
lucie.brechet@unige.ch
+41 22 379 08 52
Lucie Bréchet, PhD
principal investigator · University of Geneva (UNIGE)
Paul G Unschuld, PhD
study chair · Geneva University Hospitals (HUG)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion